Specialty billing · Oncology
The drug line is the economic engine. We bill it that way.
Get more of every chemotherapy, immunotherapy, and infusion claim paid the first time with oncology billing services from 247 Medical Billing Services, running the full revenue cycle for oncology and hematology practices across Medicare, Medicaid, and commercial payers since 2005. You get a dedicated account manager, a free 360° reporting dashboard, and HIPAA-compliant, SOC 2 Type II operations built around the buy-and-bill drug economics that decide whether an oncology practice keeps its doors open.
Vial reconciled to the recordpreparation log
units billed = documented dosewaste on its own line
An oncology practice is really two businesses stacked on top of each other: a clinical practice managing cancer, and a small specialty pharmacy carrying six- and seven-figure drug inventory through the exam suite.
Office visits, management decisions, and supportive care — the work most billing companies know how to handle.
The margin on that second business is razor thin, and it lives or dies on the accuracy of a single remittance line.
When a chemotherapy or immunotherapy agent is acquired, stored, mixed, administered, and billed exactly right, it pays cleanly and predictably.
When any link in that chain slips — the wrong number of billed units, waste that isn't captured, an infusion started before the authorization cleared — the practice absorbs the loss on a drug that may have cost more than a month of office visits.
A downcoded office visit costs a practice a modest amount; a miscounted per-milligram J-code can erase the profit on an entire treatment cycle.
It often shows up months later as a takeback rather than an up-front denial. Most billing companies treat an oncology claim the way they treat any other physician encounter and never see the drug line as the economic engine it is. That blind spot is precisely where oncology practices bleed money.
You buy the agent, hold the risk on it, infuse it, and bill the payer for both the product and the work of giving it. Every discarded portion of a single-dose vial has to be captured on its own waste line — or the practice eats the difference on a drug it already paid for.
Billed by an initial-versus-sequential-versus-concurrent structure and by the hour — not by how long the chair was occupied. Get the hierarchy wrong and the whole administration collapses into a single downcoded line.
An agent infused outside an active authorization, or off an approved pathway, is an unpaid agent. Supportive care and same-day E/M get bundled or dropped when they aren't sequenced correctly.
We manage each moving part so a claim pays to its true value — nothing bundled away, nothing left uncaptured, nothing billed in a way that invites a recoupment.
| Where money is won or lost | What it is | What we manage |
|---|---|---|
| Buy-and-bill drug (chemo, immunotherapy, biologics) | The agent itself, reported under its HCPCS J-code by exact billed units | Units reconciled to the dose administered, NDC captured, and single-dose-vial waste billed on a separate line — JW for the discarded amount, JZ to attest zero waste |
| Chemotherapy & complex-drug administration (96401–96417) | Timed IV push and infusion hierarchy for chemo and highly complex biologic agents | Correct initial-versus-sequential-versus-concurrent hierarchy, hour and each-additional-hour units, and push-versus-infusion distinction tied to the nurse's documented start and stop times |
| Therapeutic & supportive infusions (96360–96379) | Hydration, antiemetics, and other non-chemo drugs given the same day | Sequenced against the chemo administration so hydration and drug pushes bill correctly instead of bundling into the primary infusion |
| Drug waste & unit edits | Discarded single-dose-vial drug and Medically Unlikely Edits (MUEs) on high-unit J-codes | Waste captured with JW/JZ from the preparation record, and billed units held inside each drug's MUE so high-dose claims aren't automatically cut |
| E/M with same-day treatment (modifier 25) | A separately identifiable management visit on a treatment day | Modifier 25 applied only when a distinct, documented evaluation stands on its own — never stapled to a routine infusion visit |
| Prior authorization, pathways & medical necessity | Payer approval, oncology pathway programs, and NCCN/LCD coverage rules | Authorization secured before administration, the regimen documented against recognized guidelines, and diagnoses linked to the applicable NCCN and Local Coverage Determination criteria |
Outsourcing oncology billing pays off faster than in almost any other specialty, and for a specific reason: the cost of a single mistake is enormous, and the expertise needed to prevent it is narrow and hard to keep in-house.
An in-house biller who is excellent at office-visit claims can still cost you thousands per cycle the moment a per-milligram J-code, a JW waste line, or a concurrent-infusion rule enters the picture — and when that biller is out sick or leaves, the drug knowledge walks out the door with them.
When you outsource oncology billing services to us, you replace that single point of failure with a certified team that already lives inside the drug, administration, and authorization rules every day. A transaction-based fee takes the place of a salaried specialist you have to recruit, train, and cover.
The numbers that matter — clean drug lines, captured waste, authorizations that clear before infusion — become routine instead of hoped-for. For a practice where one recouped monoclonal antibody can wipe out a week of collections, that trade almost always favours specialist outsourcing.
Revenue review
A certified oncology specialist reviews your under-billed drug units, dropped waste lines, and stalled prior authorizations — and puts a number on what they are actually costing.
An oncology billing specialist will reach out within one business day.
An oncology billing specialist will reach out within one business day.
Everything it takes to move an oncology claim from the infusion note to paid, run by one certified team instead of split across vendors that hand your drug claims back and forth:
Coverage, medical-versus-pharmacy benefit routing, network status, and authorization requirements confirmed before the first infusion, not discovered on the denial.
Chemo, biologic, and immunotherapy authorizations obtained before the drug is drawn up, regimens documented against recognized pathways, and NCCN/LCD medical necessity established so the largest denial category never starts.
Agents reported by exact units under the correct HCPCS descriptor, waste captured with the right modifier, and timed administration coded to the nurse's documented times so the drug and the chair both pay in full.
Coders who read the treatment plan, MAR, and physician note together, so the J-code units, administration hierarchy, and E/M level always match the record.
Every denial worked to root cause, including unit-mismatch, waste, medical-necessity, pathway, and bundling denials, appealed inside each payer's clock with clinical documentation attached.
High-dollar aged drug claims pursued relentlessly across Medicare, Medicaid, and commercial payers, with the largest infusion lines prioritized so nothing significant ages out.
If you'd rather keep oncology billing and coding services under one roof, that's the model here — certified coders and billers on the same team, reading the same treatment record, rather than your claims shuttling between two companies that each blame the other.
Bringing us on isn't hiring a general biller who happens to accept infusion claims. It's hiring an oncology billing services company that already knows where cancer-care revenue leaks:
Every agent is reported in exact units against its descriptor, the NDC is attached, and waste is billed on its own line — so a five-figure vial pays in full instead of partially denying or getting recouped on audit.
Initial, sequential, and concurrent services are layered correctly with the right hour and additional-hour units, and IV push is distinguished from infusion, so timed treatment work never downcodes to a single line.
Chemo and immunotherapy authorizations are secured, regimens are documented against recognized pathways, and NCCN/LCD necessity is established ahead of treatment — so drugs are never given uncovered or off-pathway and written off later.
Hydration, antiemetics, growth-factor injections, and truly separate management visits are sequenced and modified correctly, so the work around the chemo gets paid instead of absorbed.
A named account manager owns your account and a live 360° dashboard shows every claim, denial, and dollar — with no long-term lock-in holding you there.
A generalist learns buy-and-bill oncology on your claims. We show up already fluent in it — and the difference lands on the remittance:
Most oncology losses trace back to the same handful of failure points. We close each one at the front end, before it becomes a denial or a recoupment:
Drug units billed that don't match the dose administered
Unit-mismatch denial and recoupment on a high-dollar J-code
We reconcile billed units to the documented dose and attach the NDC before submission
Single-dose-vial waste dropped or unattested (missing JW/JZ)
Lost waste reimbursement or an overpayment audit
We bill the discarded amount on a separate JW line and attest zero waste with JZ on every single-dose vial
Chemo administration billed without the initial/sequential/concurrent hierarchy (96401–96417)
Administration downcode to a single unit
We code one primary service and layer sequential and concurrent plus additional-hour units to the nurse's documented times
Agent infused before prior authorization clears or off an approved pathway
Full denial of the drug and the administration
We secure authorization and document the pathway-compliant regimen before the drug is drawn up
High-unit J-code exceeding the drug's MUE
Automatic unit cut or claim rejection
We hold billed units inside each drug's MUE and document the medical necessity when a higher dose is warranted
Same-day E/M without modifier 25 alongside chemo administration
E/M denial and bundling into the treatment line
We append modifier 25 only when the visit is genuinely separate and significant
Every one of these is preventable before submission rather than argued after the fact. Request a revenue review and we'll show you which of them is hitting your remittances right now.
The rules shift with the setting and the drug mix, and we bill each one to the detail it demands:
Solo and small-group clinics where a handful of infusions each week carry a large share of the month's collections.
What decides the moneyOne mishandled drug line is felt immediately
Higher volumes across chemotherapy, immunotherapy, and complex office visits.
What decides the moneyConsistent unit counting and authorization discipline
Buy-and-bill and administration billing where drug reconciliation, waste capture, and the timed hierarchy are the whole game.
What decides the moneyReconciliation, waste capture and the timed hierarchy
Anemia and clotting-disorder infusions, injectable agents, and bone-marrow work billed to their own drug and procedure rules, not lumped in with solid-tumour care.
What decides the moneyCoding to hematology's own descriptors and criteria
Split professional and facility billing, teaching-physician documentation, and heavy prior-authorization loads on advanced and investigational therapies. Practices that pair radiation with drug therapy should see our radiation oncology billing services.
What decides the moneyClean professional/facility split under a heavy auth load
Changing billers shouldn't mean a gap in cash flow, and with us it doesn't.
We work inside your existing practice-management, EHR, and oncology information systems, so no one has to relearn a platform mid-treatment.
Credentialing and payer-enrollment review run in parallel while your claims keep going out the door, and prior-authorization handoff is managed so no active regimen stalls.
Most oncology practices are fully live within a few weeks, and the high-dollar drug lines are the first thing we stabilise.
The denial drop and the faster A/R show up in the first cycles, not a quarter later.
You get your highest-dollar lines — the chemotherapy, immunotherapy, and biologic agents — paid in full the first time.
In a practice running a small specialty pharmacy through its exam suite, one miscounted unit, one dropped waste line, or one infusion started before authorization clears can erase the profit on an entire treatment cycle, often as a takeback months later. We treat the drug line as the economic engine it is. Medical billing for oncology this precise turns your thin buy-and-bill margin from a liability into a reliable line of revenue. Request a revenue review
Pick the provider that already lives in buy-and-bill economics, and you stop measuring billing mistakes in recouped monoclonal antibodies.
What outsourcing looks like with us
Outsource oncology billing to 247MBS and you replace a single in-house point of failure with a certified team that lives inside the drug, administration, and authorization rules every day — so the day your one drug-savvy biller is out sick, your highest-dollar claims still go out right.
Outsourcing trades the salary and turnover risk of that lone specialist for a transaction-based fee you pay only against claims that move, and the high-dollar drug lines are the first thing we stabilise — usually within a few weeks.
Ready to hand it off? or call +1 888-502-0537.
NO STALLNo regimen stalls and no agent written off laterDASHBOARDA live dashboard shows every claim and dollarFEEPaid only against claims that moveWhether you're a solo oncologist, a multi-provider hematology-oncology group, an in-office infusion suite, or a hospital-affiliated cancer center, our oncology billing services protect every drug unit, every administration line, and every dollar of aged A/R. Outsource oncology billing services to a team that treats buy-and-bill reconciliation, the timed administration hierarchy, prior authorization, and pathway compliance as routine — and put the revenue you're leaving on the table back where it belongs.
Prefer email? sales@247medicalbillingservices.com · For the episode-based side of cancer care, see radiation oncology billing services.